Associated Papers
Recurrent resistance mutations to lirafugratinib inform treatment sequencing in FGFR2-driven tumors.
Facchinetti F et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2026
Design, Synthesis, and Biological Evaluation of the First Novel Macrocycle-Based FGFR Inhibitors That Overcome Clinically Acquired Resistance.
Xiang S et al.
Journal of Medicinal Chemistry, 2026
Saturation mutagenesis identifies activating and resistance-inducing FGFR kinase domain mutations.
Tangermann C et al.
Nature Genetics, 2026
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Lenvatinib after progression on pemigatinib and futibatinib in FGFR2 fusion-positive biliary tract cancer with an acquired kinase point mutation.
Kleinhenz F et al.
The Oncologist, 2025
A comprehensive database for identifying and interpreting ctDNA driver genes and variants in cancer.
Wang Y et al.
Scientific Data, 2025
Genomic correlates of response and resistance to the irreversible FGFR1-4 inhibitor futibatinib based on biopsy and circulating tumor DNA profiling.
Goyal L et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2025
FGFR Inhibitors in Urothelial Cancer: From Scientific Rationale to Clinical Development.
Kwon WA
Journal of Korean Medical Science, 2024
Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies.
Facchinetti F et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2024
Application of Whole-Exome Sequencing in the Prenatal Diagnosis of Foetuses With Central Nervous System Abnormalities.
Luo C et al.
Molecular Genetics & Genomic Medicine, 2024
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial.
Rodón J et al.
Nature Medicine, 2024
A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors.
Garmezy B et al.
Cancer Research Communications, 2024
Elucidating the Role of Wildtype and Variant FGFR2 Structural Dynamics in (Dys)Function and Disorder.
Lian Y et al.
International Journal of Molecular Sciences, 2024
The molecular interaction pattern of lenvatinib enables inhibition of wild-type or kinase-mutated FGFR2-driven cholangiocarcinoma.
Spahn S et al.
Nature Communications, 2024
Postpartum related intrahepatic cholangiocarcinoma with FGFR2 fusion and severe hyperbilirubinemia with response to FGFR inhibitor pemigatinib: case report and review.
Washburn L et al.
Journal of Gastrointestinal Oncology, 2023
Author Correction: Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers.
Hsiehchen D et al.
Nature Communications, 2023
RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations.
Subbiah V et al.
Cancer Discovery, 2023
Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers.
Hsiehchen D et al.
Nature Communications, 2022
The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer.
Berchuck JE et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2022
Characterization of the cholangiocarcinoma drug pemigatinib against FGFR gatekeeper mutants.
Lin Q et al.
Communications Chemistry, 2022
Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.
Zingg D et al.
Nature, 2022
Comprehensive functional network analysis and screening of deleterious pathogenic variants in non-syndromic hearing loss causative genes.
Ray M et al.
Bioscience Reports, 2021
Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions.
Repetto M et al.
Expert Review of Clinical Pharmacology, 2021
Autopsy Case of Pfeiffer Syndrome Type 2, a Phenotype of Fibroblast Growth Factor Receptor-Associated Craniosynostosis Syndromes, with Tracheal Cartilage Sleeve and Abnormal Hyperplasia of Bronchial Cartilages.
Katsuragi SY et al.
The American Journal of Case Reports, 2021
Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance.
Krook MA et al.
British Journal of Cancer, 2021
Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib.
Silverman IM et al.
Cancer Discovery, 2021
Oncogenic fusion protein FGFR2-PPHLN1: Requirements for biological activation, and efficacy of inhibitors.
Li F et al.
Translational Oncology, 2020
Identification of pathogenic missense mutations using protein stability predictors.
Gerasimavicius L et al.
Scientific Reports, 2020
Molecular basis for receptor tyrosine kinase A-loop tyrosine transphosphorylation.
Chen L et al.
Nature Chemical Biology, 2020
The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder.
Roskoski R
Pharmacological Research, 2020
Structural basis for the activation of PLC-γ isozymes by phosphorylation and cancer-associated mutations.
Hajicek N et al.
Elife, 2019
Extremely severe scoliosis, heterotopic ossification, and osteoarthritis in a three-generation family with Crouzon syndrome carrying a mutant c.799T>C FGFR2.
Lin M et al.
Molecular Genetics & Genomic Medicine, 2019
A Conserved Allosteric Pathway in Tyrosine Kinase Regulation.
Marsiglia WM et al.
Structure (london, England : 1993), 2019
TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma.
Goyal L et al.
Cancer Discovery, 2019
Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy.
Krook MA et al.
Cold Spring Harbor Molecular Case Studies, 2019
The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.
Zill OA et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2018